The Predictive Role of HPV Integration in HSIL and Cervical Cancer
- Conditions
- HPV Integration
- Registration Number
- NCT05300243
- Lead Sponsor
- Tongji Hospital
- Brief Summary
The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 1
Inclusion Criteria
- HPV-positive patients； Patients have completed HPV detection, TCT, and HPV integration detection before surgery or biopsy； Patients with priced diagnoses accepted treatment according to ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors； Patients who are voluntary participants in this research and cooperate to follow-up with subscribing informed consent.
Exclusion Criteria
- Patients who are not suitable for the trial； Patients existing other subtype malignancy tumors are still in treatment.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tissue pathological diagnosis 1year since HPV integrated test Tissue pathological diagnosis in 1 year since HPV integrated test
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China